NDA 203341 · Pf Prism Cv
Bosulif
Bosutinib Monohydrate · Oral
NovelAccelerated approvalOrphanLast checked: Nov 19, 2026Latest source record: Mar 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Sep 4, 2012
Approved uses
5
Original approval plus efficacy supplements
Registered trials
67
6 Phase 3, 5 recruiting
FAERS reports
8,981
5,051 serious, 799 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 28, 2026.
BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 ) • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )
Mechanism: Bosutinib is a TKI. Bosutinib inhibits the BCR-ABL kinase that promotes CML; it is also an inhibitor of Src-family kinases including Src, Lyn, and Hck. Bosutinib inhibited 16 of 18 imatinib-resistant forms of BCR-ABL kinase expressed in murine myeloid cell lines. Bosutinib did not inhibit the T315I and V299L mutant cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 26, 2023 Supplement 25 · Efficacy · priority review OrphanLabelLetter
- May 14, 2021 Supplement 20 · Efficacy · priority review OrphanLabelLetter
- Dec 19, 2017 Supplement 9 · Efficacy · priority review OrphanLabelLetter
- Apr 13, 2017 Supplement 7 · Efficacy OrphanLetterLabel
- Sep 4, 2012 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalOrphanLetterLabelReview
3 products under this application
- BOSULIF · BOSUTINIB MONOHYDRATE EQ 400MG BASE · TABLET, ORAL · Prescription · TE AB
- BOSULIF · BOSUTINIB MONOHYDRATE EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB
- BOSULIF · BOSUTINIB MONOHYDRATE EQ 500MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Bosutinib" as an intervention, any sponsor and status, largest first.
Canadian Cancer Trials GroupResearch network
NCT03297606 · 720 participants (planned) · Start Mar 23, 2018 · Primary completion Dec 31, 2026
Drug: Olaparib; Dasatinib and 12 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Edmonton, Canada; Kelowna, Canada; Vancouver, Canada · 10 sites in all
PfizerPfizer (PFE)
NCT00261846 · 571 participants · Start Jan 18, 2006 · Primary completion Sep 25, 2009
Drug: Bosutinib · For: Chronic Myeloid Leukemia
Sites: Duarte, California; Denver, Colorado; Washington D.C., District of Columbia · 111 sites in all
- A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02130557 · 536 participants · Start Jul 15, 2014 · Primary completion Aug 11, 2016
Drug: Bosutinib; Imatinib · For: Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
Sites: Anaheim, California; Atlanta, Georgia; Honolulu, Hawaii · 189 sites in all
- Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CMLPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00574873 · 502 participants · Start Feb 5, 2008 · Primary completion Aug 31, 2010
Drug: Bosutinib; imatinib · For: Chronic Myeloid Leukemia
Sites: Anaheim, California; Beverly Hills, California; Fountain Valley, California · 165 sites in all
- A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIsPivotal-lookingRecruiting
Enliven TherapeuticsIndustry
NCT07905183 · 450 participants (planned) · Start Dec 31, 2026 · Primary completion Dec 31, 2028
Drug: ELVN-001; TKI · For: Chronic Myeloid Leukemia (CML); Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML
Sites: Atlanta, Georgia; Indianapolis, Indiana; Morristown, New Jersey · 4 sites in all
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04971226 · 405 participants · Start Oct 6, 2021 · Primary completion Nov 28, 2023
Drug: Imatinib; Nilotinib and 3 more · For: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Sites: Denver, Colorado; Fort Myers, Florida; Tallahassee, Florida · 110 sites in all
- Asciminib Roll-over StudyRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04877522 · 347 participants (planned) · Start Aug 30, 2022 · Primary completion Aug 30, 2030
Drug: Asciminib single agent; Imatinib and 4 more · For: Chronic Myelogenous Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sites: Ann Arbor, Michigan; St Louis, Missouri; New York, New York · 88 sites in all
- Study of Olverembatinib (HQP1351) in Patients With CML-CPPivotal-lookingRecruiting
Ascentage Pharma Group Inc.Industry
NCT06423911 · 333 participants (planned) · Start Feb 5, 2024 · Primary completion Jun 30, 2027
Drug: olverembatinib; Bosutinib · For: Chronic Myeloid Leukemia; CML; CML, Chronic Phase
Sites: Birmingham, Alabama; Anchorage, Alaska; Goodyear, Arizona · 163 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea2,078
- nausea1,020
- fatigue728
- vomiting544
- death538
- rash492
- pleural effusion458
- neoplasm progression373
- dyspnoea364
- headache339
- off label use330
- drug intolerance318
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 3 |
| 2010 | 7 |
| 2011 | 7 |
| 2012 | 60 |
| 2013 | 270 |
| 2014 | 398 |
| 2015 | 540 |
| 2016 | 504 |
| 2017 | 575 |
| 2018 | 697 |
| 2019 | 966 |
| 2020 | 865 |
| 2021 | 817 |
| 2022 | 851 |
| 2023 | 993 |
| 2024 | 737 |
| 2025 | 484 |
| 2026 | 207 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bosulif (Bosutinib)
2024 spending
$235M
Beneficiaries
1,981
15,541 claims
Per beneficiary
$118,784
$357.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $123,423,995 |
| 2021 | $147,656,080 |
| 2022 | $170,022,055 |
| 2023 | $199,137,491 |
| 2024 | $235,311,823 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, et al. · Leukemia 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D, Mauro MJ, Boquimpani C, et al. · Blood 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. · J Clin Oncol 2018 · Comparative Study, Multicenter Study
- Maiden voyage: induced pluripotent stem cell-based drug screening for amyotrophic lateral sclerosis.
Ito D, Morimoto S, Takahashi S, et al. · Brain 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Interventions for preventing the progression of autosomal dominant polycystic kidney disease.
St Pierre K, Cashmore BA, Bolignano D, et al. · Cochrane Database Syst Rev 2024 · Systematic Review
- Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.
Mauro MJ, Minami Y, Hochhaus A, et al. · Blood Adv 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Pf Prism Cv
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.